Wylie Burke

Wylie Burke

Auto-generated profile, based on publicly available information

Wylie Burke

Department of Bioethics and Humanities, University of Washington, Seattle (W.B.).

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
WBWylie Burke
Wylie Burke
AAArmand H. Matheny Antommaria
Armand H. Matheny Antommaria
RBRobin Bennett
Robin Bennett
JBJeffrey Botkin
Jeffrey Botkin
ECEllen Clayton
Ellen Clayton
RZRon Zimmern
Ron Zimmern

1 July 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
WBWylie Burke
Wylie Burke
EPErik Parens
Erik Parens
WCWendy K. Chung
Wendy K. Chung
SBSara M. Berger
Sara M. Berger
PAPaul S. Appelbaum
Paul S. Appelbaum
Genomic testing often identifies genetic variants of uncertain clinical significance. This article explains how the variants lead to harms. It also describes strategies to reduce the harms and the ... Genomic tests expand diagnostic and screening opportunities but also identify genetic variants of uncertain clinical significance (VUSs). Only a minority of VUSs are likely to prove pathogenic when...

8 July 1998 in JAMA
Verified
Journal Article
Closed access
PDF file
WBWylie Burke
Wylie Burke
ETElizabeth Thomson
Elizabeth Thomson
MKMuin J. Khoury
Muin J. Khoury
SMSharon M. McDonnell
Sharon M. McDonnell
NPNancy Press
Nancy Press
FCFrancis S. Collins
Francis S. Collins
Review from JAMA — Hereditary Hemochromatosis — Gene Discovery and Its Implications for Population-Based Screening — Objective.—To evaluate the role of genetic testing in screening for hereditary hemochromatosis to help guide clinicians, policymakers, and researchers.Participants.—An expert panel was convened on March 3, 1997, by the Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI), with expertise in epidemiology, genetics, hepatology, iron overload disorders, molecular biology, public health, and the ethical, legal, and social implications surrounding the discovery and use of genetic information.Evidence.—The group reviewed evidence regarding the clinical presentation, natural history, and genetics of hemochromatosis, including current data on the candidate gene for hemochromatosis (HFE) and on the ethical and health policy implications of genetic testing for this disorder.Consensus Process.—Consensus was achieved by group discussion confirmed by a voice vote. A draft of the consensus statement was prepared by a writing committee and subsequently reviewed and revised by all members of the expert group over a 1-year period.Conclusions.—Genetic testing is not recommended at this time in population-based screening for hereditary hemochromatosis, due to uncertainties about prevalence and penetrance of HFE mutations and the optimal care of asymptomatic people carrying HFE mutations. In addition, use of a genetic screening test raises concerns regarding possible stigmatization and discrimination. Tests for HFE mutations may play a role in confirming the diagnosis of hereditary hemochromatosis in persons with elevated serum iron measures, but even this use is limited by uncertainty about genotype-phenotype correlations. To address these questions, the expert group accorded high priority to population-based research to define the prevalence of HFE mutations, age and sex-related penetrance of different HFE genotypes, interactions between HFE genotypes and environmental modifiers, and psychosocial outcomes of genetic screening for hemochromatosis.

1 February 2003 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
WBWylie Burke
Wylie Burke
MFMegan Fesinmeyer
Megan Fesinmeyer
KRKate Reed
Kate Reed
LHLindsay Hampson
Lindsay Hampson
CCChris Carlsten
Chris Carlsten

5 December 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
WBWylie Burke
Wylie Burke
Classic genetic tests indicate, either directly or indirectly, the presence of DNA variants associated with rare but highly penetrant disorders such as Huntington's disease or multiple endocrine neoplasia type 2. This article not only reviews these classic tests but also shows how novel genetic tests can reveal the presence of DNA variants that are more logically considered risk factors for a given condition.

1 December 2004 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
WBWylie Burke
Wylie Burke
RZRon L. Zimmern
Ron L. Zimmern